R. Abi-habib, J. Urieto, S. Liu, S. Leppla, N. Duesbery et al., BRAF status and mitogen-activated protein/extracellular signal, 2005.

V. Alexeev and K. Yoon, Distinctive Role of the cKit Receptor Tyrosine Kinase Signaling in Mammalian Melanocytes, Journal of Investigative Dermatology, vol.126, issue.5, pp.1102-1110, 2006.
DOI : 10.1038/sj.jid.5700125

M. Alsina, R. Fonseca, E. Wilson, A. Belle, E. Gerbino et al., Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma, Blood, vol.103, issue.9, pp.3271-3277, 2004.
DOI : 10.1182/blood-2003-08-2764

A. Birck, V. Ahrenkiel, J. Zeuthen, K. Hou-jensen, and P. Guldberg, Mutation and Allelic Loss of the PTEN/MMAC1 gene in Primary and Metastatic Melanoma Biopsies, Journal of Investigative Dermatology, vol.114, issue.2, pp.277-280, 2000.
DOI : 10.1046/j.1523-1747.2000.00877.x

T. Burgess, A. Coxon, S. Meyer, J. Sun, R. K. Tsuruda et al., Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor with Therapeutic Potential against Hepatocyte Growth Factor/c-Met-Dependent Human Tumors, Cancer Research, vol.66, issue.3, pp.1721-1729, 2006.
DOI : 10.1158/0008-5472.CAN-05-3329

J. Christensen, J. Burrows, and R. Salgia, c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention, Cancer Letters, vol.225, issue.1, pp.1-26, 2005.
DOI : 10.1016/j.canlet.2004.09.044

S. Cohen, L. Ho, S. Ranganathan, J. Abbruzzese, R. Alpaugh et al., Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma, Journal of Clinical Oncology, vol.21, issue.7, pp.1301-1306, 2003.
DOI : 10.1200/JCO.2003.08.040

E. Collisson, A. De, H. Suzuki, S. Gambhir, and M. Kolodney, Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade, Cancer Res, vol.63, pp.5669-5673, 2003.

J. Curtin, K. Busam, D. Pinkel, and B. Bastian, Somatic Activation of KIT in Distinct Subtypes of Melanoma, Journal of Clinical Oncology, vol.24, issue.26, pp.4340-4346, 2006.
DOI : 10.1200/JCO.2006.06.2984

D. Dai, M. Martinka, and G. Li, Prognostic Significance of Activated Akt Expression in Melanoma: A Clinicopathologic Study of 292 Cases, Journal of Clinical Oncology, vol.23, issue.7, pp.1473-1482, 2005.
DOI : 10.1200/JCO.2005.07.168

J. Damen, L. Liu, P. Rosten, R. Humphries, A. Jefferson et al., The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase., Proceedings of the National Academy of Sciences, vol.93, issue.4, pp.1689-1693, 1996.
DOI : 10.1073/pnas.93.4.1689

H. Davies, G. Bignell, C. Cox, P. Stephens, S. Edkins et al., Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, pp.949-954, 2002.
DOI : 10.1006/geno.2000.6354

A. Dhillon, S. Hagan, O. Rath, and W. Kolch, MAP kinase signalling pathways in cancer, Oncogene, vol.4, issue.22, pp.3279-3290, 2007.
DOI : 10.1158/0008-5472.CAN-05-0115

J. Du, A. Miller, H. Widlund, M. Horstmann, S. Ramaswamy et al., MLANA/MART1 and SILV/PMEL17/GP100 Are Transcriptionally Regulated by MITF in Melanocytes and Melanoma, The American Journal of Pathology, vol.163, issue.1, pp.333-343, 2003.
DOI : 10.1016/S0002-9440(10)63657-7

L. Dudkin, M. Dilling, P. Cheshire, F. Harwood, M. Hollingshead et al., Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition, Clin Cancer Res, vol.7, pp.1758-1764, 2001.

N. Dumaz, R. Hayward, J. Martin, L. Ogilvie, D. Hedley et al., In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling, Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling, pp.9483-9491, 2006.
DOI : 10.1158/0008-5472.CAN-05-4227

N. Dumaz and R. Marais, Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on The Anniversary Prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels, FEBS Journal, vol.21, issue.324, pp.3491-3504, 2003.
DOI : 10.1073/pnas.262787199

T. Eisen, T. Ahmad, K. Flaherty, M. Gore, S. Kaye et al., Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis, British Journal of Cancer, vol.22, issue.5, pp.581-586, 2006.
DOI : 10.1038/sj.onc.1208841

B. Escudier, N. Lassau, E. Angevin, J. Soria, L. Chami et al., Phase I Trial of Sorafenib in Combination with IFN ??-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma, Clinical Cancer Research, vol.13, issue.6, pp.1801-1809, 2007.
DOI : 10.1158/1078-0432.CCR-06-1432

L. Fecher, S. Cummings, M. Keefe, and R. Alani, Toward a Molecular Classification of Melanoma, Journal of Clinical Oncology, vol.25, issue.12, pp.1606-1620, 2007.
DOI : 10.1200/JCO.2006.06.0442

K. Flaherty, Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma, Clinical Cancer Research, vol.12, issue.7, pp.2366-2370, 2006.
DOI : 10.1158/1078-0432.CCR-05-2505

F. Vara, J. Casado, E. De-castro, J. Cejas, P. Belda-iniesta et al., PI3K/Akt signalling pathway and cancer, Cancer Treatment Reviews, vol.30, issue.2, pp.193-204, 2004.
DOI : 10.1016/j.ctrv.2003.07.007

M. Garnett and R. Marais, Guilty as charged, Cancer Cell, vol.6, issue.4, pp.313-319, 2004.
DOI : 10.1016/j.ccr.2004.09.022
URL : http://doi.org/10.1016/j.ccr.2004.09.022

L. Garraway, H. Widlund, M. Rubin, G. Getz, A. Berger et al., Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma, Nature, vol.64, issue.7047, pp.117-122, 2005.
DOI : 10.1038/nature03664

P. Guldberg, P. Thor-straten, A. Birck, V. Ahrenkiel, A. Kirkin et al., Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma, Cancer Res, vol.57, pp.3660-3663, 1997.

R. Halaban, The Regulation of Normal Melanocyte Proliferation, Pigment Cell Research, vol.13, issue.1, pp.4-14, 2000.
DOI : 10.1034/j.1600-0749.2000.130103.x

J. Hancock, Ras proteins: different signals from different locations, Nature Reviews Molecular Cell Biology, vol.4, issue.5, pp.373-384, 2003.
DOI : 10.1038/nrm1105

S. Hingorani, M. Jacobetz, G. Robertson, M. Herlyn, and D. Tuveson, Suppression of BRAF(V599E) in human melanoma abrogates transformation, Cancer Res, vol.63, pp.5198-5202, 2003.

M. Karasarides, A. Chiloeches, R. Hayward, D. Niculescu-duvaz, I. Scanlon et al., B-RAF is a therapeutic target in melanoma, Oncogene, vol.23, issue.37, pp.6292-6298, 2004.
DOI : 10.1038/sj.onc.1207785

Y. Kimura, N. Jones, M. Kluppel, M. Hirashima, K. Tachibana et al., Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages, Proceedings of the National Academy of Sciences, vol.101, issue.16, pp.6015-6020, 2004.
DOI : 10.1073/pnas.0305363101

H. Koo, M. Vanbrocklin, M. Mcwilliams, S. Leppla, N. Duesbery et al., Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase, Proceedings of the National Academy of Sciences, vol.99, issue.5, pp.3052-3057, 2002.
DOI : 10.1073/pnas.052707699

K. Kuba, K. Matsumoto, K. Date, H. Shimura, M. Tanaka et al., HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice, Cancer Res, vol.60, pp.6737-6743, 2000.

L. Larribere, C. Hilmi, M. Khaled, C. Gaggioli, K. Bille et al., The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis, Genes & Development, vol.19, issue.17, pp.1980-1985, 2005.
DOI : 10.1101/gad.335905

N. Lassam and S. Bickford, Loss of c-kit expression in cultured melanoma cells, Oncogene, vol.7, pp.51-56, 1992.

J. Lennartsson, T. Jelacic, D. Linnekin, and R. Shivakrupa, Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit, Stem Cells, vol.14, issue.1, pp.16-43, 2005.
DOI : 10.1634/stemcells.2004-0117

C. Levy, M. Khaled, and D. Fisher, MITF: master regulator of melanocyte development and melanoma oncogene, Trends in Molecular Medicine, vol.12, issue.9, pp.406-414, 2006.
DOI : 10.1016/j.molmed.2006.07.008

G. Li, H. Schaider, K. Satyamoorthy, Y. Hanakawa, K. Hashimoto et al., Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development, Oncogene, vol.20, issue.56, pp.8125-8135, 2001.
DOI : 10.1038/sj.onc.1205034

N. Li, D. Batt, and M. Warmuth, B-Raf kinase inhibitors for cancer treatment, Curr Opin Investig Drugs, vol.8, pp.452-456, 2007.

J. Lin and D. Fisher, Melanocyte biology and skin pigmentation, Nature, vol.111, issue.7130, pp.843-850, 2007.
DOI : 10.1038/nature05660

P. Lorusso, J. Rinehart, L. Nabell, G. Croghan, M. Varterasian et al., Phase 1 2 clinical study of a second generation oral ?, 2005.

M. Malumbres and M. Barbacid, RAS oncogenes: The first 30 years, Nature Reviews Cancer, vol.245, issue.9, pp.459-465, 2003.
DOI : 10.1038/nrc1193

B. Manning and L. Cantley, AKT/PKB Signaling: Navigating Downstream, Cell, vol.129, issue.7, pp.1261-1274, 2007.
DOI : 10.1016/j.cell.2007.06.009
URL : http://doi.org/10.1016/j.cell.2007.06.009

K. Margolin, J. Longmate, T. Baratta, T. Synold, S. Christensen et al., CCI-779 in metastatic melanoma, Cancer, vol.4, issue.5, pp.1045-1048, 2005.
DOI : 10.1002/cncr.21265

F. Mccormick, Cancer: Survival pathways meet their end, Nature, vol.428, issue.6980, pp.267-269, 2004.
DOI : 10.1038/428267a

G. Mcgill, R. Haq, E. Nishimura, and D. Fisher, c-Met Expression Is Regulated by Mitf in the Melanocyte Lineage, Journal of Biological Chemistry, vol.281, issue.15, pp.10365-10373, 2006.
DOI : 10.1074/jbc.M513094200

M. Mckay and D. Morrison, Integrating signals from RTKs to ERK/MAPK, Oncogene, vol.13, issue.22, pp.3113-3121, 2007.
DOI : 10.1074/jbc.M413327200

S. Meloche and J. Pouyssegur, The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition, Oncogene, vol.12, issue.22, pp.3227-3239, 2007.
DOI : 10.1074/jbc.272.47.29967
URL : https://hal.archives-ouvertes.fr/hal-00319874

P. Natali, M. Nicotra, I. Sures, E. Santoro, A. Bigotti et al., Expression of c-kit receptor in normal and transformed human nonlymphoid tissues, Cancer Res, vol.52, pp.6139-6143, 1992.

F. Noonan, T. Otsuka, S. Bang, M. Anver, and G. Merlino, Accelerated ultraviolet radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice, Cancer Res, vol.60, pp.3738-3743, 2000.

T. Otsuka, H. Takayama, R. Sharp, G. Celli, W. Larochelle et al., Anver M 1998; c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype, Cancer Res, vol.58, pp.5157-5167

D. Panka, M. Atkins, and J. Mier, Targeting the Mitogen-Activated Protein Kinase Pathway in the Treatment of Malignant Melanoma, Clinical Cancer Research, vol.12, issue.7, pp.2371-2375, 2006.
DOI : 10.1158/1078-0432.CCR-05-2539

B. Peruzzi and D. Bottaro, Targeting the c-Met Signaling Pathway in Cancer, Clinical Cancer Research, vol.12, issue.12, pp.3657-3660, 2006.
DOI : 10.1158/1078-0432.CCR-06-0818

N. Puri, S. Ahmed, V. Janamanchi, M. Tretiakova, O. Zumba et al., c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma, Clinical Cancer Research, vol.13, issue.7, pp.2246-2253, 2007.
DOI : 10.1158/1078-0432.CCR-06-0776

J. Rinehart, A. Adjei, P. Lorusso, D. Waterhouse, J. Hecht et al., Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer, Journal of Clinical Oncology, vol.22, issue.22, pp.4456-4462, 2004.
DOI : 10.1200/JCO.2004.01.185

R. Roskoski and . Jr, Structure and regulation of Kit protein-tyrosine kinase???The stem cell factor receptor, Biochemical and Biophysical Research Communications, vol.338, issue.3, pp.1307-1315, 2005.
DOI : 10.1016/j.bbrc.2005.09.150

S. Schubbert, K. Shannon, and G. Bollag, Hyperactive Ras in developmental disorders and cancer, Nature Reviews Cancer, vol.91, issue.4, pp.295-308, 2007.
DOI : 10.1038/nrc2109

A. Sharma, N. Trivedi, M. Zimmerman, D. Tuveson, C. Smith et al., Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors, Cancer Research, vol.65, issue.6, pp.2412-2421, 2005.
DOI : 10.1158/0008-5472.CAN-04-2423

M. Siddiqui and L. Scott, Imatinib, Drugs, vol.28, issue.7, pp.805-820, 2007.
DOI : 10.2165/00003495-200767050-00012

L. Simpson and R. Parsons, PTEN: Life as a Tumor Suppressor, Experimental Cell Research, vol.264, issue.1, pp.29-41, 2001.
DOI : 10.1006/excr.2000.5130

K. Smalley and T. Eisen, Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells, International Journal of Cancer, vol.105, issue.2, pp.165-175, 2003.
DOI : 10.1002/ijc.11064

D. Solit, L. Garraway, C. Pratilas, A. Sawai, G. Getz et al., BRAF mutation predicts sensitivity to MEK inhibition, Nature, vol.436, issue.7074, pp.358-362, 2006.
DOI : 10.1038/nature04304
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306236

J. Stahl, A. Sharma, M. Cheung, M. Zimmerman, J. Cheng et al., Deregulated Akt3 Activity Promotes Development of Malignant Melanoma, Cancer Research, vol.64, issue.19, pp.7002-7010, 2004.
DOI : 10.1158/0008-5472.CAN-04-1399

C. Thallinger, W. Poeppl, B. Pratscher, M. Mayerhofer, P. Valent et al., CCI-779 plus Cisplatin Is Highly Effective against Human Melanoma in a SCID Mouse Xenotranplantation Model, Pharmacology, vol.79, issue.4, pp.207-213, 2007.
DOI : 10.1159/000101008

C. Thallinger, J. Werzowa, W. Poeppl, F. Kovar, B. Pratscher et al., Comparison of a Treatment Strategy Combining CCI-779, 2007.

J. Thompson, R. Scolyer, and R. Kefford, Cutaneous melanoma, The Lancet, vol.365, issue.9460, pp.687-701, 2005.
DOI : 10.1016/S0140-6736(05)70937-5

N. Thompson and J. Lyons, Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery, Current Opinion in Pharmacology, vol.5, issue.4, pp.350-356, 2005.
DOI : 10.1016/j.coph.2005.04.007

S. Ugurel, R. Hildenbrand, A. Zimpfer, L. Rosee, P. Paschka et al., Lack of clinical efficacy of imatinib in metastatic melanoma, British Journal of Cancer, vol.2, issue.8, pp.1398-1405, 2005.
DOI : 10.1200/JCO.20.3.719

K. Vance and C. Goding, The Transcription Network Regulating Melanocyte Development and Melanoma, Pigment Cell Research, vol.155, issue.8, pp.318-325, 2004.
DOI : 10.1046/j.1523-1747.2003.12562.x

E. Weisberg, P. Manley, S. Cowan-jacob, A. Hochhaus, and J. Griffin, Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia, Nature Reviews Cancer, vol.108, issue.5, pp.345-356, 2007.
DOI : 10.1038/nrc2126

C. Wellbrock, M. Karasarides, and R. Marais, The RAF proteins take centre stage, Nature Reviews Molecular Cell Biology, vol.9, issue.11, pp.875-885, 2004.
DOI : 10.1096/fj.02-1096com

C. Wellbrock and R. Marais, Elevated expression of MITF counteracts B-RAF???stimulated melanocyte and melanoma cell proliferation, The Journal of Cell Biology, vol.14, issue.5, pp.703-708, 2005.
DOI : 10.1006/excr.2000.4803

S. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. Mcnabola et al., BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis, Cancer Research, vol.64, issue.19, pp.7099-7109, 2004.
DOI : 10.1158/0008-5472.CAN-04-1443

A. Winter-vann and P. Casey, Opinion: Post-prenylation-processing enzymes as new targets in oncogenesis, Nature Reviews Cancer, vol.9, issue.5, pp.405-412, 2005.
DOI : 10.1083/jcb.119.3.617

T. Yeh, V. Marsh, B. Bernat, J. Ballard, H. Colwell et al., Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor, Clinical Cancer Research, vol.13, issue.5, pp.1576-1583, 2007.
DOI : 10.1158/1078-0432.CCR-06-1150